[go: up one dir, main page]

BR0011116A - Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas - Google Patents

Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas

Info

Publication number
BR0011116A
BR0011116A BR0011116-3A BR0011116A BR0011116A BR 0011116 A BR0011116 A BR 0011116A BR 0011116 A BR0011116 A BR 0011116A BR 0011116 A BR0011116 A BR 0011116A
Authority
BR
Brazil
Prior art keywords
salt
treatment
nsaid
releases
enancièmero
Prior art date
Application number
BR0011116-3A
Other languages
English (en)
Inventor
Arne Eek
Johan Raud
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902027A external-priority patent/SE9902027D0/xx
Priority claimed from SE9904704A external-priority patent/SE9904704D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0011116A publication Critical patent/BR0011116A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"USOS DE UMA NSAID QUE LIBERA NO COMO UM SAL FARMACEUTICAMENTE ACEITáVEL OU UM ENANCIÈMERO DO MESMO, E DE UMA NSAID QUE LIBERA NO E DE UM INIBIDOR DE BOMBA DE PRóTON SUSCETìVEL A ACIDO OU UM SAL DO MESMO OU UM ENANCIÈMERO OU DE UM SAL DO ENANCIÈMERO, MéTODO PARA O TRATAMENTO DE UMA INFECçãO BACTERIANA, E, FORMULAçãO FARMACêUTICA ADEQUADA PARA USO NO TRATAMENTO DE INFECçõES BACTERIANAS". A presente invenção descreve o uso de NSAIDS que liberam NO, especialmente NSAIDS que liberam NO de fórmula (1) ou um sal ou enanciómero farmaceuticamente aceitável das mesmas, para a manufatura de um medicamento para o tratamento de infecções bacterianas, especialmente causadas ou mediadas por Helicobacter pylori. é também descrito o uso de uma NSAID que libera NO em combinação com um inibidor de bomba de próton suscetível a ácido para o tratamento de infecções bacterianas.
BR0011116-3A 1999-06-01 2000-05-25 Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas BR0011116A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902027A SE9902027D0 (sv) 1999-06-01 1999-06-01 New use
SE9904704A SE9904704D0 (sv) 1999-12-21 1999-12-21 New use
PCT/SE2000/001071 WO2000072838A1 (en) 1999-06-01 2000-05-25 New use of compounds as antibacterial agents

Publications (1)

Publication Number Publication Date
BR0011116A true BR0011116A (pt) 2002-02-19

Family

ID=26663588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011116-3A BR0011116A (pt) 1999-06-01 2000-05-25 Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas

Country Status (27)

Country Link
US (2) US6593339B1 (pt)
EP (1) EP1196155B1 (pt)
JP (1) JP4818516B2 (pt)
KR (1) KR100671392B1 (pt)
CN (1) CN1165298C (pt)
AR (1) AR024159A1 (pt)
AT (1) ATE272396T1 (pt)
AU (1) AU780678B2 (pt)
BG (1) BG106158A (pt)
BR (1) BR0011116A (pt)
CA (1) CA2373653C (pt)
CZ (1) CZ20014289A3 (pt)
DE (1) DE60012745T2 (pt)
EE (1) EE200100647A (pt)
HK (1) HK1045814B (pt)
HU (1) HUP0201502A3 (pt)
IL (1) IL146407A0 (pt)
IS (1) IS6185A (pt)
MX (1) MXPA01012295A (pt)
NO (1) NO20015855L (pt)
NZ (1) NZ515317A (pt)
PL (1) PL352744A1 (pt)
RU (1) RU2252032C2 (pt)
SK (1) SK17392001A3 (pt)
TR (1) TR200103474T2 (pt)
TW (1) TWI243672B (pt)
WO (1) WO2000072838A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348741C (en) 1998-10-30 2010-04-20 Nitromed Inc. Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6706724B2 (en) 2000-12-21 2004-03-16 Nitromed, Inc. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
ATE474559T1 (de) 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2487414A1 (en) * 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
JP2005539089A (ja) 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法
JP2005538110A (ja) 2002-07-29 2005-12-15 ニトロメッド インコーポレーティッド シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
AU2003254282A1 (en) 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
WO2004041803A1 (en) * 2002-11-05 2004-05-21 Merck Frosst Canada & Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP2058275A1 (en) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20050054714A1 (en) * 2003-07-17 2005-03-10 Benito Munoz Nitric oxide releasing drugs for Alzheimer's disease
CA2540407A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
PT1906938E (pt) * 2005-07-26 2011-01-17 Nicox Sa Formulação farmacêutica de derivados de nitrooxi de aine
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
AU2011330768A1 (en) 2010-11-15 2013-05-30 Merz Pharma Gmbh & Co. Kgaa Dipeptide analogs for treating conditions associated with amyloid fibril formation
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104815330A (zh) * 2015-05-22 2015-08-05 杜林� 乙酸类非甾体抗炎药的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IL98680A0 (en) 1991-06-30 1992-07-15 Yeda Res & Dev Hydroxamate derivatives and pharmaceutical compositions containing them
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
WO1995009831A1 (en) * 1993-10-06 1995-04-13 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
AU7972294A (en) * 1993-10-07 1995-05-01 Entremed, Inc Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
BR9507634A (pt) * 1994-05-10 1997-09-23 Nicox Sa Compostos ou suas composições e uso dos mesmos
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5785689A (en) 1996-07-18 1998-07-28 Act Medical, Inc. Endoscopic catheter sheath position control
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents

Also Published As

Publication number Publication date
KR20020015334A (ko) 2002-02-27
AU780678B2 (en) 2005-04-07
HK1045814B (en) 2005-04-01
EP1196155A1 (en) 2002-04-17
TR200103474T2 (tr) 2002-04-22
HUP0201502A2 (en) 2002-08-28
JP4818516B2 (ja) 2011-11-16
EE200100647A (et) 2003-02-17
IS6185A (is) 2001-11-29
AU5262300A (en) 2000-12-18
IL146407A0 (en) 2002-07-25
CA2373653A1 (en) 2000-12-07
JP2003500442A (ja) 2003-01-07
CN1354658A (zh) 2002-06-19
PL352744A1 (en) 2003-09-08
NO20015855L (no) 2002-01-30
NO20015855D0 (no) 2001-11-30
DE60012745D1 (de) 2004-09-09
HUP0201502A3 (en) 2003-03-28
RU2252032C2 (ru) 2005-05-20
TWI243672B (en) 2005-11-21
BG106158A (en) 2002-06-28
AR024159A1 (es) 2002-09-04
ATE272396T1 (de) 2004-08-15
CN1165298C (zh) 2004-09-08
US6593339B1 (en) 2003-07-15
DE60012745T2 (de) 2005-09-15
SK17392001A3 (sk) 2002-07-02
KR100671392B1 (ko) 2007-01-22
US20040048917A1 (en) 2004-03-11
CA2373653C (en) 2011-03-15
HK1045814A1 (en) 2002-12-13
NZ515317A (en) 2004-05-28
WO2000072838A1 (en) 2000-12-07
MXPA01012295A (es) 2002-07-30
EP1196155B1 (en) 2004-08-04
CZ20014289A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
NO20076083L (no) Mukoadhesive xyloglukaninneholdende formuleringer som er anvendelige i medisinske anordninger og i farmasoytiske formuleringer
DK0413528T3 (da) Amphotere præparater og polymere former af alphahydroxysyrer og deres terapeutiske anvendelse
BRPI0408559A (pt) composições farmacêuticas dispersìveis para o tratamento de mastite e distúrbios óticos
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR9908617A (pt) Nitroto inorgânico e ácido orgânico em combinação como uma composição antiviral tópica.
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
BR0306214A (pt) Composto de 4-oxoquinolina e uso deste como inibidor de integrase de hiv
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BRPI0508933A (pt) composições para entrega tópica
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
PT914110E (pt) Metodo de modulacao da micro-circulacao
BRPI0416376A (pt) composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BRPI0414305A (pt) sistema de liberação de drogas por via oral
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NICOX S.A. (FR)

Free format text: TRANSFERIDO DE: ASTRAZENECA AB

B25G Requested change of headquarter approved

Owner name: NICOX S.A. (FR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070016104/RJ DE 07/02/2007.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10( VIII ),13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.